Drug-induced side effects affecting the gastrointestinal tract
暂无分享,去创建一个
[1] A. Ide. Gastric ulcer. , 2020, Minnesota medicine.
[2] F. Chan,et al. Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors , 2006, The American Journal of Gastroenterology.
[3] G. Papatheodoridis,et al. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] J. Hippisley-Cox,et al. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.
[5] C. Hawkey,et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin , 2005, Alimentary pharmacology & therapeutics.
[6] Luis Rodrigo,et al. A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use , 2005, The American Journal of Gastroenterology.
[7] G. Thiéfin,et al. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. , 2005, Joint, bone, spine : revue du rhumatisme.
[8] Claire Saadeh. Chemotherapy‐ and Radiotherapy‐Induced Oral Mucositis: Review of Preventive Strategies and Treatment , 2005, Pharmacotherapy.
[9] C. Hawkey,et al. Nonsteroidal antiinflammatory drugs and the small intestine , 2005, Current opinion in gastroenterology.
[10] R. Pwu,et al. Risk estimates for drugs suspected of being associated with Stevens‐Johnson syndrome and toxic epidermal necrolysis: a case‐control study , 2005, Internal medicine journal.
[11] B. Lewis,et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] V. Wong,et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. , 2005, The New England journal of medicine.
[13] V. Wong,et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. , 2004, Gastroenterology.
[14] J. Leighton,et al. Diaphragm disease after use of nonsteroidal anti-inflammatory agents: first report of diagnosis with capsule endoscopy. , 2004, Journal of clinical gastroenterology.
[15] F. Chan,et al. Prevention of non‐steroidal anti‐inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment , 2004, Alimentary pharmacology & therapeutics.
[16] L. Biancone,et al. Rofecoxib and early relapse of inflammatory bowel disease: an open‐label trial , 2004, Alimentary pharmacology & therapeutics.
[17] A. Price. Pathology of drug-associated gastrointestinal disease. , 2003, British journal of clinical pharmacology.
[18] V. Lee,et al. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease , 2003, Alimentary pharmacology & therapeutics.
[19] J. Avorn,et al. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. , 2003, The Journal of rheumatology.
[20] T. Schnitzer,et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. , 2003, Gastroenterology.
[21] F. Chan,et al. Arthritis treatment in Hong Kong — cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents , 2002, Alimentary pharmacology & therapeutics.
[22] R. Lindsay,et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. , 2002, Mayo Clinic proceedings.
[23] A. Ottani,et al. Dual acting anti-inflammatory drugs: a reappraisal. , 2001, Pharmacological research.
[24] C. Funk,et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.
[25] F. Chan,et al. Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Approaching the end of the controversy in the new millennium, or room for more debate? , 2001, Journal of Gastroenterology.
[26] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[27] L. Joseph,et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. , 2001, British journal of clinical pharmacology.
[28] R. Fisher,et al. Ischemic colitis during treatment with alosetron. , 2001, Gastroenterology.
[29] C. Patrono. Aspirin: new cardiovascular uses for an old drug. , 2001, The American journal of medicine.
[30] Jacob,et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID‐enteropathy in the rat , 2000, Alimentary pharmacology & therapeutics.
[31] P. Isakson,et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison , 1999, The Lancet.
[32] I Larzillière,et al. [Esophagitis associated with the use of alendronate]. , 1999, Gastroenterologie clinique et biologique.
[33] M. Wolfe,et al. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.
[34] Harp Jb. Orlistat for the long-term treatment of obesity. , 1999 .
[35] M. Gammon,et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[36] G. Singh,et al. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. , 1998, The American journal of medicine.
[37] David Schultz,et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.
[38] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[39] G. Naylor,et al. Oesophageal stricture associated with alendronic acid , 1996, The Lancet.
[40] H T Hatoum,et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. , 1996, Archives of internal medicine.
[41] H. Baillie-Johnson. Octreotide in the management of treatment-related diarrhoea , 1996, Anti-Cancer Drugs.
[42] A. Zinsmeister,et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly , 1995, Digestive Diseases and Sciences.
[43] G. Weaver,et al. Nonsteroidal antiinflammatory drugs are associated with gastric outlet obstruction. , 1995, Journal of clinical gastroenterology.
[44] K. Davis. Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.
[45] N. Brousse,et al. Drug induced lymphocytic colitis. , 1994, Gut.
[46] A. Smyth,et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes , 1994, The Lancet.
[47] R. Riddell,et al. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. , 1992, Gut.
[48] A. Parker,et al. Colonic strictures in a patient on long-term non-steroidal anti-inflammatory drugs. , 1992, Gastrointestinal endoscopy.
[49] S. Sabanathan,et al. Drug-induced esophagitis. , 1991, The American journal of gastroenterology.
[50] M. W. Han,et al. Ischemic colitis in a crack abuser , 1991, Digestive Diseases and Sciences.
[51] D. Graham,et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. , 1987, The American journal of gastroenterology.
[52] A. Blower,et al. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. , 1987, Gut.
[53] H. Satoh,et al. Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics. , 1983, Gastroenterology.
[54] Y. Ishihara,et al. Effects of cholestyramine and synthetic hydrotalcite on acute gastric or intestinal lesion formation in rats and dogs , 1981, Digestive Diseases and Sciences.
[55] D. Rampton,et al. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. , 1981, Postgraduate medical journal.
[56] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[57] D. Graham,et al. Visible small-intestinal mucosal injury in chronic NSAID users. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[58] J. Leichter,et al. Drug-associated gingival enlargement: case report and review of aetiology, management and evidence-based outcomes of treatment. , 2005, Journal of the New Zealand Society of Periodontology.
[59] P. Schoenfeld,et al. Safety Profile of Tegaserod, a 5-HT4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome , 2004, Drug safety.
[60] A. Hui. Encyclopedia of gastroenterology || gastric ulcer , 2004 .
[61] James G. Anderson,et al. A systems approach to preventing adverse drug events. , 2003, Studies in health technology and informatics.
[62] F. Chan. Helicobacter pylori and nonsteroidal anti-inflammatory drugs. , 2001, Gastroenterology clinics of North America.
[63] K. Iwakiri,et al. Effect of nifedipine administration (10 mg) on esophageal acid exposure time , 2000, Journal of Gastroenterology.
[64] J. Harp. Orlistat for the long-term treatment of obesity. , 1999, Drugs of today.
[65] N. Davies,et al. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. , 1997, Gastroenterology.
[66] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[67] S. Syngal,et al. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. , 1995, Arthritis and rheumatism.
[68] L. Knodel. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs , 1994 .
[69] F. Halter,et al. Diaphragm disease of the ascending colon. Association with sustained-release diclofenac. , 1993, Journal of clinical gastroenterology.
[70] R. Haddock,et al. Nabumetone. Evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans. , 1990, Drugs.